Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.

[1]  E. B. Butler,et al.  Disparities in the Treatment and Outcome of Stage I Non-Small-Cell Lung Cancer in the 21st Century. , 2019, Clinical lung cancer.

[2]  E. Taioli,et al.  Persistence of racial disparities in early‐stage lung cancer treatment , 2019, The Journal of thoracic and cardiovascular surgery.

[3]  S. Chanock,et al.  Racial Disparities in Lung Cancer Survival: The Contribution of Stage, Treatment, and Ancestry , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  B. Halmos,et al.  Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community , 2018, Clinical lung cancer.

[5]  Sandra J. Japuntich,et al.  Racial Disparities in Lung Cancer Screening: An Exploratory Investigation. , 2017, Journal of the National Medical Association.

[6]  W. Black,et al.  Racial and Ethnic Disparities in Early‐Stage Lung Cancer Survival , 2017, Chest.

[7]  V. Vinh-Hung,et al.  Lung Adenocarcinoma Survival in EGFR-Mutated African-Caribbean Patients: A Multicenter Study in the French West Indies , 2017, Targeted Oncology.

[8]  David R Williams,et al.  Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations , 2017, JAMA oncology.

[9]  V. Ninane,et al.  Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer , 2016, Lung Cancer.

[10]  M. Kris,et al.  Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium , 2016, Cancer.

[11]  K. Coombes,et al.  A Pooled Analysis , 2015 .

[12]  W. Pao,et al.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. , 2015, JAMA oncology.

[13]  G. Bepler,et al.  Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  M. Socinski,et al.  Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses , 2014, Clinical pharmacology and therapeutics.

[15]  A. Majid,et al.  Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. , 2013, Lung cancer.

[16]  Y. Bensouda,et al.  Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  C. Langer,et al.  Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? , 2013, Lung cancer.

[18]  Liang Cheng,et al.  Molecular pathology of lung cancer: key to personalized medicine , 2012, Modern Pathology.

[19]  G. Giaccone,et al.  Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry , 2011, Oncogene.

[20]  G. Bepler,et al.  Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  M. Ladanyi,et al.  Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  F. Cappuzzo,et al.  Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jie Liang,et al.  Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer , 2009, Clinical Cancer Research.

[24]  F. Hirsch,et al.  EGFR testing in lung cancer is ready for prime time. , 2009, The Lancet. Oncology.

[25]  M. Hidalgo,et al.  Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes , 2007, Clinical Cancer Research.

[26]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[27]  Leah E. Mechanic,et al.  Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[28]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[29]  U. Ladabaum,et al.  Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Xianglin L. Du,et al.  Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Tanoue.  Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans , 2012 .

[32]  B. Lum,et al.  The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition , 2007, European Journal of Clinical Pharmacology.